How could #MostFavoredNation drug pricing affect #biopharma companies' customers & channel partners? Let's find out: bit.ly/45wvq9v

How might #MFN pricing for #pharmaceuticals impact dealmaking in pharma? Here are some thoughts on that >> bit.ly/4e8Dr7b

Recently, Blue Matter convened a group of 16 C-level execs from UK #biotech firms to discuss the impact of #MFN & other US policies on the UK biotech sector. Here's a summary >> bit.ly/4kCuFAz

Recently, members of our team attended #ASCO25. Here, they outline the most important issues, data, & takeaways from their perspective >> bit.ly/4dWjqjN #cancer #oncology #CancerResearch #biotech #pharmaceutical

Highlights from #EULAR2025, the annual congress of EULAR >> bit.ly/4n9UjOI #rheumatology #autoimmune #inflammatorydiseases #biotech #pharmaceuticals

Why & how should #biopharma companies incorporate #DecisionScience into their decision making processes? In this paper, we provide the answer >> bit.ly/3HVVYaC

Our #team members work together & volunteer together! Recently, members of our San Fran team took part in a drive with Raphael House to provide back-to-school supplies for local kids who need them. Learn more about Raphael House here: raphaelhouse.org #BestTeamEver

It’s Summer Meeting time! These meetings provide a great opportunity for our team members to enjoy each other’s company & some fun activities in a non-work setting. Recently, our London & Zurich teams met in Surrey, UK for some archery, laser clay shooting, country walks, & more.

Our NYC & Boston offices just wrapped up an unforgettable company off-site at the Saybrook Point Resort & Marina in CT. Moments like these matter. Over the past 3 days, we talked strategy, built trust, & strengthened relationships. #BestTeamEver #TeamBuilding #ConsultingJobs

When a #biopharma company evolves from single asset company to one that's developing a portfolio, its decision-making processes become much more complex. In this article, we describe some key challenges (& solutions) related to portfolio forecasting >> bit.ly/4mkfsox

#Biopharma #Analytics & Tech Enthusiasts: Are you ready to take your career to the next level? Blue Matter Insights, our team specializing in primary research, data analytics, & technology might be the answer! Learn more & apply here >> bluematterconsulting.applytojob.com/apply #ConsultingCareers

Don't miss our upcoming presentation at the Intellus Institute, Sept 10, 2025. Learn more here: bluematterconsulting.com/about-us/news-… #IntellusWW #biotech #pharmaceuticals #behavioralscience

NEW! >> Blue Matter is pleased to announce that it has acquired Spekle Solutions, a biopharma-focused analytics firm with offices in Woodland Hills, CA & Pune, India.  To the entire Spekle team: Welcome to Blue Matter! Read more here >> bit.ly/4lUKkLg

In this article, our team analyzes #biopharma deals from the 1st half of 2025 & compares the level of activity to previous periods. We also take a brief look at what it might mean for the future >> bit.ly/46UZpbt

Recently, Blue Matter's Jenna Riffell attended the annual Congress of the EADV in Paris. In this article, Jenna identifies some key themes from the meeting & offers insights on the #dermatology market bit.ly/4pICrvI #biotech #pharmaceuticals #eadv25

New #WhitePaper: We look back at the 1st half of 2025 to examine how the current #biopharma deal-making environment compares with prior periods. We explore key statistics around deal size & volume, deal types, therapeutic areas of interest, & more. >> bit.ly/42Y1Wzm

NEW >> What methods can growing #biopharma companies use to optimize investments across a diverse portfolio of assets or programs? In this article, we address that question & explore how #decisionscience can help >> bit.ly/3IXfK6y #biotech #pharmaceuticals

NEW > In #RareDiseases, finding patients can be quite a challenge. In this case study, Eric Vogel & Nikhil Bhat show how #MachineLearning can make the job easier >> bit.ly/4hiKhbO #biopharma #biotech #pharmaceutical #raredisease #patientfinding

Speed has always been an important factor in #pharmaceutical commercialization. In this paper, we share common factors that can act as "brakes" on companies, plus a framework for building speed without sacrificing quality >> bit.ly/3L9ngvR #biotech #pharmaceuticals

The US #biopharma #MarketAccess landscape has been volatile during 2025. In this latest article, we explore the factors that are driving uncertainty. Plus, we provide a look ahead to 2026 >> bit.ly/47rEzQ3 #MFNDrugPricing #biotech #pharmaceuticals